Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex - Involvement of Na+/K+-ATPase

Neurochemistry International

Volumn 44, Issue 7, 2004, Pages 529-538

  Steffens, Marc ^a   Feuerstein, Thomas J ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anandamide; Arachidonic acid; Cannabinoids; Dopamine uptake; Na+ K + ATPase; Serotonin uptake; Synaptosomes; WIN55212 2

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; ADENOSINE TRIPHOSPHATE; ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; DOPAMINE; OUABAIN; SEROTONIN;

ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BRAIN SYNAPTOSOME; COMPETITIVE INHIBITION; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISSOCIATION CONSTANT; DOPAMINE UPTAKE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INACTIVATION; NEOCORTEX; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE; STATISTICAL SIGNIFICANCE;

STROPHANTHUS GRATUS;

EID: 0842267121     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2003.08.009     Document Type: Article

References (38)

1. Altman D.G. Statistics in medical journals: developments in the 1980s. Stat. Med. 10:1991;1897-1913.
2. Banerjee S.P., Snyder S.H., Mechoulam R. Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. J. Pharmacol. Exp. Ther. 194:1975;74-81.
3. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256:1999;377-380.
4. Chan P.H., Fishman R.A. Alteration of membrane integrity and cellular constituents by arachidonic acid in neuroblastoma and glioma cells. Brain Res. 248:1982;151-157.
5. +)-ATPase activity in brain slices and synaptosomes by arachidonic acid. J. Neurochem. 40:1983;309-316.
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
7. D'Ambra T.E., Estep K.G., Bell M.R., Eissenstat M.A., Josef K.A., Ward S.J., Haycock D.A., Baizman E.R., Casiano F.M., Beglin N.C.et al. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J. Med. Chem. 35:1992;124-135.
8. Deadwyler S.A., Hampson R.E., Bennett B.A., Edwards T.A., Mu J., Pacheco M.A., Ward S.J., Childers S.R. Cannabinoids modulate potassium current in cultured hippocampal neurons. Receptors Channels. 1:1993;121-134.
9. Devane W.A., Dysarz F.A. III, Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
10. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
11. 2 receptors. Mol. Pharmacol. 48:1995;443-450.
12. Feuerstein T.J., Limberger N. Mathematical analysis of the control of neurotransmitter release by presynaptic receptors as a supplement to experimental data. Naunyn-Schmiedeberg's Arch. Pharmacol. 359:1999;345-359.
13. 3H ]-5-hydroxytryptamine Br. J. Pharmacol. 88:1986;677-684.
14. Gardner M.J., Altman D.G. Confidence intervals rather than P values: estimation rather than hypothesis testing. Br. Med. J. (Clin. Res. Ed.). 292:1986;746-750.
15. Gatley S.J., Gifford A.N., Volkow N.D., Lan R., Makriyannis A. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. 307:1996;331-338.
16. Gifford A.N., Ashby C.R. Jr. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN55212-2, and is potentiated by the cannabinoid antagonist, SR141716A. J. Pharmacol. Exp. Ther. 277:1996;1431-1436.
17. Herkenham J., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
18. Howlett A.C., Qualy J.M., Khachatrian L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313.
19. L'Hirondel A., Cheramy A., Godeheu G., Glowinski J. Effects of arachidonic acid on dopamine synthesis, spontaneous release, and uptake in striatal synaptosomes from the rat. J. Neurochem. 64:1995;1406-1409.
20. Lowry O.H., Rosebrough N.J., Farr A., Randall R.J. Protein measurements with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
21. Lupp A., Bär K.I., Lücking C.H., Feuerstein T.J. Different effects of serotonin (5-HT) uptake blockers in caudate nucleus and hippocampus of the rabbit: role of monoamine oxidase in dopaminergic terminals. Psychopharmacology. 106:1992;118-126.
22. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. U.S.A. 89:1992;3825-3829.
23. 9-tetrahydrocannabinol reduces γ-aminobutyric acid uptake in the globus pallidus. Eur. J. Pharmacol. 308:1996;161-164.
24. 1 receptors: similarities to presynaptic imidazoline and edg receptors. Neurochem. Int. 40:2002;157-167.
25. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
26. Okuda T., Haga T., Kanai Y., Endou H., Ishihara T., Katsura I. Identification and characterization of the high-affinity choline transporter. Nat. Neurosci. 3:2000;120-125.
27. Reith M.E., O'Reilly C.A. Inhibition of serotonin uptake into mouse brain synaptosomes by ionophores and ion-channel agents. Brain Res. 521:1990;347-351.
28. Rhoads D.E., Ockner R.K., Peterson N.A., Raghupathy E. Modulation of membrane transport by free fatty acids: inhibition of synaptosomal sodium-dependent amino acid uptake. Biochemistry. 22:1983;1965-1970.
29. Romero J., de Miguel R., Ramos J.A., Fernandez-Ruiz J.J. The activation of cannbinoid receptors in striatonigral GABAergic neurons inhibited GABA uptake. Life Sci. 62:1998;351-363.
30. 9-Tetrahydrocannabinol facilitates striatal dopaminergic transmission. Pharmacol. Biochem. Behav. 33:1989;397-400.
31. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends. Pharmacol. Sci. 22:2001;565-572.
32. + M-current in hippocampal CA1 neurons. J. Neurosci. 20:2000;51-58.
33. 1 receptors: evidence for an endocannabinoid tone in the human neocortex. Neuroscience. 120:2003;455-465.
34. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentation. Nature. 388:1997;773-777.
35. +-ATPase leading to inhibition and inactivation. Biochim. Biophys. Acta. 1024:1990;32-40.
36. Twitchell W., Brown S., Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78:1997;43-50.
37. Volterra A., Trotti D., Cassutti P., Tromba C., Salvaggio A., Melcangi R.C., Racagni G. High sensitivity of glutamate uptake to extracellular free archidonic acid levels in rat cortical synaptosomes and astrocytes. J. Neurochem. 59:1992;600-606.
38. Zhang L., Reith M.E. Regulation of the functional activity of the dopamine transporter by the arachidonic acid pathway. Eur. J. Pharmacol. 315:1996;345-354.